Try our Advanced Search for more refined results

Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. et al

  1. October 16, 2017

    Judge Hacks Away At Allergan's Restasis Patents

    A federal judge ruled Monday that claims in several patents covering Allergan PLC's dry-eye drug Restasis are invalid, dealing a blow to the drugmaker just weeks after it transferred the patents to a Native American tribe in an effort to shield them from review at the Patent Trial and Appeal Board.

  2. October 13, 2017

    Allergan, Generic Cos. Debate If Tribal Patent Deal Is A 'Sham'

    Generic-drug makers told a Texas federal court Friday that Allergan's transfer of patents for the dry-eye treatment Restasis to a Native American tribe in a bid to escape Patent Trial and Appeal Board review is a "sham" and "pure hypocrisy," while Allergan argued the deal is a valid transaction.

  3. October 11, 2017

    Tribe Bought Patents With Immunity Promise, Allergan Says

    The Saint Regis Mohawk Tribe agreed to assert immunity during patent challenges and extend that immunity to Allergan Inc. in exchange for Allergan giving it ownership of patents protecting the dry eye treatment Restasis, the drugmaker said Tuesday after a federal judge in Texas told it to prove the deal wasn't a "sham."

  4. October 10, 2017

    Allergan Ordered To Prove Tribe Patent Deal Isn't A 'Sham'

    Allergan Inc. needs to prove that its controversial transfer of four patents for the dry eye treatment Restasis to the Saint Regis Mohawk Tribe was more than a "sham" before the tribe can be added to infringement litigation against Teva, Mylan and others, a federal judge in Texas said.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!